Brokerages expect that Inogen Inc (NASDAQ:INGN) will post $91.38 million in sales for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Inogen’s earnings, with estimates ranging from $89.30 million to $92.90 million. Inogen reported sales of $95.29 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 4.1%. The company is expected to announce its next earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Inogen will report full-year sales of $371.47 million for the current financial year, with estimates ranging from $370.13 million to $372.60 million. For the next year, analysts forecast that the company will post sales of $408.01 million, with estimates ranging from $403.17 million to $412.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Inogen.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Wednesday, August 7th. The medical technology company reported $0.45 EPS for the quarter, missing the Zacks’ consensus estimate of $0.50 by ($0.05). Inogen had a return on equity of 13.34% and a net margin of 11.24%. The company had revenue of $101.10 million during the quarter, compared to the consensus estimate of $106.88 million. During the same period in the previous year, the business earned $0.65 earnings per share. Inogen’s revenue was up 3.9% on a year-over-year basis.
INGN has been the subject of a number of analyst reports. BidaskClub lowered Inogen from a “sell” rating to a “strong sell” rating in a report on Friday, August 9th. Leerink Swann lowered Inogen from an “outperform” rating to a “market perform” rating in a report on Thursday, August 8th. Piper Jaffray Companies cut their price target on Inogen from $140.00 to $80.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. lowered Inogen from a “neutral” rating to an “underweight” rating and set a $72.00 price target for the company. in a report on Wednesday, July 3rd. Finally, Svb Leerink reissued a “market perform” rating and set a $47.00 price objective (down previously from $78.00) on shares of Inogen in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. Inogen has an average rating of “Hold” and a consensus price target of $82.17.
In other Inogen news, Director Loren L. Mcfarland acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average price of $42.93 per share, with a total value of $42,930.00. Following the completion of the purchase, the director now owns 4,481 shares of the company’s stock, valued at $192,369.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Heath Lukatch acquired 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average cost of $43.01 per share, with a total value of $86,020.00. Following the purchase, the director now directly owns 5,481 shares of the company’s stock, valued at approximately $235,737.81. The disclosure for this purchase can be found here. 4.54% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Advisor Group Inc. raised its position in Inogen by 71.4% during the second quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 192 shares in the last quarter. Hanson McClain Inc. purchased a new stake in Inogen during the first quarter valued at about $50,000. TRUE Private Wealth Advisors purchased a new stake in Inogen during the second quarter valued at about $66,000. Steward Partners Investment Advisory LLC purchased a new stake in Inogen during the second quarter valued at about $119,000. Finally, Victory Capital Management Inc. purchased a new stake in Inogen during the first quarter valued at about $163,000.
Shares of Inogen stock traded up $0.38 during trading hours on Wednesday, reaching $48.79. The company had a trading volume of 1,076 shares, compared to its average volume of 456,192. Inogen has a one year low of $41.19 and a one year high of $285.89. The business has a fifty day simple moving average of $48.57 and a 200 day simple moving average of $71.80. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 6.82. The firm has a market cap of $1.07 billion, a PE ratio of 21.27, a price-to-earnings-growth ratio of 2.78 and a beta of 1.50.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Story: Does the discount rate affect the economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.